Clinical Study on the Intervention of Gastric Compound for Patients with Middle-late Gastric Cancer of Spleen Deficiency and Stasis Toxin
10.3969/j.issn.1005-5304.2015.03.006
- VernacularTitle:胃复方干预治疗脾虚瘀毒型中晚期胃癌临床研究
- Author:
Dongfang LI
;
Jiangli FAN
;
Yunqi WANG
;
Zhenyang LIU
;
Hui LIANG
;
Yuming LI
;
Min ZHOU
;
Hong WU
;
Jiao JIAO
- Publication Type:Journal Article
- Keywords:
gastric compound;
middle-late stage gastric cancer;
spleen deficiency and stasis toxin;
quality of life
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2015;(3):20-23,24
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect of gastric compound on patients with middle-late gastric cancer of spleen deficiency and stasis toxin. Methods Ninety patients with middle-late gastric cancer of spleen deficiency and stasis toxin were randomly divided into combined group, chemotherapy group, and gastric compound group, 30 cases in each group. Patients in the combined group were treated with gastric compound and chemotherapy;patients in the chemotherapy group were treated with placebo;patients in the gastric compound group were treated with gastric compound. The changes of QLQ-C30 scale integral, fatigue scale intergral, TCM symptom intergral, Karnofsky integral, and toxic and side effects of digestive tract and myelosuppression were observed to evaluate the effect of gastric compound on quality of life in patients. Results The changes of QLQ-C30 scale integral, fatigue scale intergral, TCM symptom intergral, Karnofsky intergal in combined group were better than those in chemotherapy group and gastric compound group, with statistical significance (P<0.05). The changes of fatigue scale intergral and TCM symptom intergral in gastric compound group were better than those in chemotherapy group, with statistical significance (P<0.05). The myelosuppression and toxic and side effects of digestive tract of combined group was lighter than those of chemotherapy group, with statistical significance (P<0.01). Conclusion Gastric compound combined with chemotherapy can improve quality of life in patients with middle-late gastric cancer of spleen deficiency and stasis toxin, and reduce myelosuppression and toxic and side effects of digestive tract.
